Browsing: KCAS

Immunogenicity FEATURE_panel_jan_2019
0

Webinar live date: Thursday 10 January 2018 07:00 [PST] 10:00 [EST] 15:00 [GMT]. In this free panel discussion, our experts will provide insights into their own research with immunogenicity including the challenges they have had to overcome, key trends they have seen and their future outlook of the development of this field.

Immunogenicity Bz KCas image
0

Immunogenicity is the patient’s ability to generate antibodies, specific to the ‘dosed protein therapeutic’. In this blog post, Franklin Spriggs (KCAS; KS, USA) explains the importance of antibody-drug antibody assays and how data can be used towards safety profiles.

spotlight Image for BZ
0

KCAS, LLC optimized a primary and secondary stimulation assay of Peripheral Blood Mononuclear Cell (PBMC)
samples from a clinical trial in order to characterize the immune response to a multi-valent peptide vaccine. In partnership with our pharmaceutical sponsor, an agreed upon set of samples were tested by KCAS, LLC to optimize a culture method, culture time course, stimulation, and re-stimulation. These samples were also used to optimize surface and intracellular staining of the following panel: CD45, CD3 CD8, PD1, CCR7, IFNγ, TNFα, IL-2 and viability dye. Upon review of the initial optimized method, the full cohort of patient samples were cultured, treated, stained, and analyzed.

In the Zone lab
0

Learn more about the pros and cons of investing in new technologies or sticking with more traditional techniques, as well as about the key questions that should be considered before making the decision. In this infographic, we investigate the pros and cons of utilizing four different technologies available for large molecule analysis: colorimetric ELISA, Meso-Scale Diagnostics, Time Resolved Fluorescence and Quanterix Simoa.

1 2